🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationCompounded tirzepatide formulation challenges — looking for input

Compounded tirzepatide formulation challenges — looking for input

Dr.EndoIndy Sat, Apr 13, 2024 at 8:50 AM 43 replies 2,583 viewsPage 1 of 9
This thread is more than 23 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Apr 13, 2024 at 10:15 AM#1

Can someone give me a current state of affairs on compounded tirzepatide as of Q1 2026? It feels like the landscape changes every week.

Last I heard, FDA removed tirzepatide from the shortage list in late 2024 and has been going after compounders. But I'm still seeing some pharmacies advertising it. What's the actual legal status? And what are people paying?

1 8mia_MS2
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Apr 13, 2024 at 10:32 AM#2

Here's the current status as of March 2026:

Legal status: Complicated. FDA removed tirzepatide from the shortage list in October 2024 and has been issuing warning letters and cease-and-desist orders to compounders. HOWEVER, multiple lawsuits are challenging these enforcement actions, and some pharmacies have obtained temporary restraining orders allowing them to continue compounding.

Availability: Reduced but not eliminated. Several 503B facilities stopped voluntarily. Others are still compounding under legal protection from court orders. Some 503A pharmacies argue they're exempt from the enforcement because they compound on a patient-specific basis.

Pricing (where available):

  • Compounded tirzepatide 10mg vial: $150-275/month
  • Compounded tirzepatide 30mg vial: $300-450 (multi-month supply at lower doses)

Compare to brand Mounjaro/Zepbound at $1,050-1,200/month without insurance.

38 5PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 35 others
Reply Quote Save Share Report
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Apr 13, 2024 at 10:49 AM#3

The key legal case right now is the litigation in the 5th Circuit involving the Outsourcing Facilities Association. The core argument is whether compounded tirzepatide using a different salt form constitutes an "essentially a copy" of branded Mounjaro/Zepbound. If the courts rule it's NOT a copy, compounding could resume broadly.

There's also a constitutional argument about FDA overreach in enforcement. Some pharmacies argue that FDA's administrative determination that the shortage ended is arbitrary and capricious because patients still can't access the medication due to cost.

It's a legal mess. But the practical takeaway: compounded tirzepatide is still available from some pharmacies, just fewer than before.

44 24tommy_boulder, hyun_seoul, jim_asheville and 41 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
SallyK_inj
Member
567
2,345
Jul 2024
Iowa
Apr 13, 2024 at 11:06 AM#4

So if I find a pharmacy still compounding it, am I taking any legal risk as a patient? Can FDA come after me for buying it?

10 3tane_welly, Dr.PathRoch, mona_PHX and 7 others
Reply Quote Save Share Report
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Apr 13, 2024 at 11:23 AM#5

No. FDA enforcement actions target pharmacies and prescribers, not patients. You are not breaking any law by filling a valid prescription for a compounded medication. The legal risk sits entirely with the pharmacy and potentially the prescriber.

That said, availability risk is real. If your pharmacy gets shut down mid-treatment, you're back to square one (see the "pharmacy shut down" thread).

Last edited: Apr 13, 2024 at 4:23 PM
34 24mona_PHX, andrew_nyc, Dr.EndoEP and 31 others
Reply Quote Save Share Report
1239

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register